CD8A and neoplasm: Intratumoral tumor-specific SCL CD8+ T cells are known to mediate the responses to PD-1/PD-L1 blockade and adoptive T cell immunotherapies (Krishna et al., 2020; Siddiqui et al., 2019) and are supplied from a reservoir of precursors in the tumor dLN (Connolly et al., 2021; Schenkel et al., 2021).